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High levels of fatty acid synthase (FAS) expression have been observed in several cancers, including breast, prostate, colon and lung
carcinoma, compared with their respective normal tissue. We present data that show high levels of FAS protein in human and rat
glioma cell lines and human glioma tissue samples, as compared to normal rat astrocytes and normal human brain. Incubating glioma
cells with the FAS inhibitor cerulenin decreased endogenous fatty acid synthesis by approximately 50%. Cell cycle analysis
demonstrated a time- and dose-dependent increase in S-phase cell arrest following cerulenin treatment for 24h. Further, treatment
with cerulenin resulted in time- and dose-dependent decreases in glioma cell viability, as well as reduced clonogenic survival.
Increased apoptotic cell death and PARP cleavage were observed in U251 and SNB-19 cells treated with cerulenin, which was
independent of the death receptor pathway. Overexpressing Bcl-2 inhibited cerulenin-mediated cell death. In contrast, primary rat
astrocytes appeared unaffected. Finally, RNAi-mediated knockdown of FAS leading to reduced FAS enzymatic activity was associated
with decreased glioma cell viability. These findings suggest that FAS might be a novel target for antiglioma therapy.
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In 2006, 18820 individuals living in the US will be diagnosed with
primary brain cancer (Jemal et al, 2006). The most common and
most lethal primary brain tumour in adults is glioblastoma
multiforme. Glioblastoma multiforme represents one of the most
challenging of all cancers to treat successfully, characterised not
only by aggressive proliferation and expansion but also by
inexorable tumour invasion into distant brain tissue (Kew and
Levin, 2003). Improvements in multimodality treatments including
surgery, radiotherapy, and the recent addition of temozolomide
have improved median survival, but this is still only approximately
14 months (Stupp et al, 2005) and long-term survival is dismal.
The development of novel biological therapies for primary brain
tumours remains an urgent need. Current cancer treatment is
rapidly evolving in parallel with an understanding of tumour
biology (Weiss, 2000; Karpati and Nalbantoglu, 2003). Genetic
abnormalities and differential gene expression between normal
and cancer cells can provide novel targets for anticancer therapy
(Lang et al, 1999; Bansal and Engelhard, 2000; Grill et al, 2001).
Fatty acid synthase (FAS) is a 270kDa cytosolic multifunctional
polypeptide and is the primary enzyme required for catalysing the
conversion of dietary carbohydrates to fatty acids (Wakil, 1989).
Normal cells preferentially use circulating dietary fatty acids for
the synthesis of new structural lipids. Thus, FAS expression is
generally low to undetectable in normal human tissues, other than
the liver and adipose tissue. In contrast, FAS is overexpressed in
many human tumours, including carcinoma of the breast
(Milgraum et al, 1997; Wang et al, 2001b), prostate (Epstein
et al, 1995; Swinnen et al, 2002), colon (Rashid et al, 1997), ovary
(Gansler et al, 1997), endometrium (Pizer et al, 1998b),
mesothelium (Gabrielson et al, 2001), lung (Piyathilake et al,
2000), thyroid (Vlad et al, 1999), and stomach (Kusakabe et al,
2002). Abnormally active endogenous fatty acid metabolism
appears to be important for cancer cell proliferation and survival
(Ookhtens et al, 1984). Moreover, overexpression of FAS in breast,
prostate, and thyroid cancers has been associated with more
aggressive malignancies (Epstein et al, 1995; Gansler et al, 1997;
Vlad et al, 1999; Swinnen et al, 2002). The preferential expression
of FAS in cancer cells suggests that FAS could be a promising
target for antitumour therapy (Kuhajda, 2006).
Inhibitors of FAS have been used to study the loss of FAS
function in tumour cells. The first identified ‘specific’ inactivator
of FAS, cerulenin, (2R,3 S)-2,3-epoxy-4-oxo-7,10-trans,trans-
dodecadienamide, is a natural antibiotic product of the fungus
Cephalosporium ceruleans (Omura, 1976). Cerulenin irreversibly
inhibits FAS by binding covalently to the active site cysteine thiol
in the b-ketoacyl-synthase domain (Funabashi et al, 1989).
Cerulenin is selectively cytotoxic to a number of established
human cancer cell lines, including breast (Gabrielson et al, 2001),
colon (Pizer et al, 1998a), and prostate (Furuya et al 1997; Pizer
et al, 2001). Kuhajda et al (2000) reported that cerulenin inhibited
fatty acid synthesis in tumour cells in a dose-dependent manner;
the cytotoxic effect of cerulenin to human breast tumour cells
generally paralleled the level of endogenous fatty acid synthesis.
Fatty acid synthase inhibition by cerulenin leads to apoptotic cell
death in breast, prostate, and colon cancer cells (Furuya et al, 1997;
Huang et al, 2000; Li et al, 2001). However, cerulenin’s chemical
instability renders it inappropriate as a systemic anticancer agent.
C75, a potent derivative of cerulenin and a more stable form of FAS
inhibitor, has been tested recently for its anti-breast tumour effects
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s(Kuhajda et al, 2000; Pizer et al, 2000). In vivo and in vitro studies
have confirmed the selective toxicity of C75 against tumour cells.
C75-mediated inhibition of FAS increases malonyl-CoA levels
and inhibits CPT-1 activity, preventing the oxidation of newly
synthesised fatty acids. High levels of malonyl-CoA and CPT-1
inhibition might represent a mechanism, whereby FAS inhibition
leads to tumour cell death (Pizer et al, 2000). C75 treatment of
mesothelioma and prostate cancer xenografts in nude mice led to
significant inhibition of tumour growth (Gabrielson et al, 2001;
Pizer et al, 2001). Subcutaneous xenografts of MCF7 breast cancer
cells in nude mice treated with C75 showed fatty acid synthesis
inhibition, apoptosis, and inhibition of tumour growth to less than
12.5% of control volumes, without comparable toxicity in normal
tissues (Pizer et al, 2000).
More recently, an activity-based proteomics strategy revealed in
vitro and in vivo antitumour activity for Orlistat, an FDA-approved
drug used for treating obesity. Orlistat is a novel inhibitor of the
thioesterase domain of FAS that inhibited prostate cancer cell proli-
feration, induced apoptosis, and inhibited the growth of PC-3 human
tumour xenografts implanted in nude mice (Kridel et al, 2004).
To date, there is little information regarding FAS expression in
brain tumours. Slade et al (2003) reported that significantly larger
amounts of FAS protein were detected in the neuroblastoma cell
line SK-N-SH compared with that in the human fibroblast cell line
Hs27. We hypothesised that FAS would be highly expressed in
glioma cells and that inhibition of FAS would lead to glioma cell
death. In this paper, we show that this hypothesis appears to be
correct. For the first time, we show upregulation of FAS in glioma
cells and human glioma tissue, dose-and time-dependent decreases
in glioma cell viability, and clonogenic survival with FAS
inhibition, as well as increased apoptotic cell death. These studies
identify FAS as a potential target for glioma therapy.
MATERIALS AND METHODS
Cell culture
Human U373, U118, U87, and U138 as well as rat C6 glioma cell
lines were obtained from the American Type Culture Collection
(Rockville, MD, USA). The ethyl nitrosourea-induced rat 36B10
glioma cell line was obtained from Dr Vincent Traynelis, Division of
Neurosurgery, Department of Surgery, University of Iowa (Spence &
Coates, 1978) and routinely maintained in high glucose DMEM
containing 5% bovine calf serum, 2mML -glutamine, 100IUml
 1
penicillin, 100mgml
 1 streptomycin, and 0.1mM non-essential
amino acids (all from GIBCO, Gaithersburg, MD, USA) at 371C
with 5% CO2 in air. Cells were trypsinised and reseeded at a 1:5
dilution every 3 days. Human U251 and SNB-19 glioma cell lines
were a kind gift of Dr Sue Hess (Department of Radiation Oncology,
WFUSM) and were maintained in DMEM/F12 and F10 media
supplemented with 10% foetal bovine serum (FBS), 2mM
L-glutamine, 100IUml
 1 penicillin, and 100mgml
 1 streptomycin.
Primary rat astrocytes were isolated from 1- to 2-day-old Sprague–
Dawley rat pups as described previously (Murphy, 1990). Cortices
were removed from the rat pups; the meninges were stripped and
homogenised. After incubation with trypsin for 15min in a 371C
shaking water bath, the homogenate was centrifuged and the pellet
was resuspended in a trypsin inhibitor/DNAse solution, triturated,
and layered over a bovine serum albumin solution. The cell pellet
was resuspended and maintained in MEM medium with 1%
L-glutamine, 10% FBS, and 6gl
 1 glucose at 371C in a humidified
atmosphere of 5% CO2 until ready to use.
Human glioma and normal brain tissue
Human brain tissue lysates were prepared by homogenisation in
modified RIPA buffer (150mM sodium chloride, 50mM Tris-HCl
(pH 7.4), 1mM phenyl methyl sulphonyl fluoride, 1% Triton X-100,
1% sodium deoxycholic acid, 0.1% sodium dodecyl sulphate (SDS),
5mgml
 1 aprotinin, and 5mgml
 1 leupeptin). The tissue lysates
were centrifuged for 10min at 10000r.p.m. to remove debris and
the supernatants were stored at  801C until use.
Fatty acid synthesis
To test whether cerulenin inhibits FAS activity in glioma cells, lipid
synthesis was determined using
14C-labelled acetic acid methods as
described previously (Rashid et al, 1997). Briefly, 5 10
5 SNB-19,
U251, and C6 cells were plated into 24-well plates for 24h (three
replicates per group). After incubation with 5mgml
 1 cerulenin for
2h at 371C, the cells were washed and were then incubated with
14C-labelled acetate for 4h. Total lipids were extracted and
14C
counts determined using liquid scintillation counting.
Western blot analysis
Western blot analysis was performed as described previously
(Zhao et al, 2001). Cells were lysed using lysis buffer containing
50mM Tris (pH 7.0), 1mM EDTA, 150mM NaCl, 1mM PMSF,
1mgml
 1 aprotinin, 1mgml
 1 leupeptin, 1mM Na3VO4, and 1mM
NaF, and stored in aliquots at  701C until use. Ten micrograms of
cell lysate was mixed with an equal volume of sample buffer
containing 62.5mM Tris/HCl (pH 6.8), 10% glycerol, 2% SDS,
5% b-mercaptoethanol, and 2–3 drops of saturated bromophenol
solution, denatured by boiling, and separated in a 7.5%
polyacrylamide mini-gel at a constant voltage of 120V for 2h.
The proteins were transferred by electrophoresis at 100V for 1h to
ECL nitrocellulose membrane (Amersham, Arlington Heights, IL,
USA). The membranes were blocked for 1h at room temperature
in 5% (wtvol
 1) non-fat dry milk in TTBS containing 20mM Tris-
HCl (pH 7.0), 137mM NaCl, and 0.05% (volvol
 1) Tween-20. After
washing in TTBS for 2 10min, the membranes were then blocked
with 5% non-fat milk and probed with either primary mouse anti-
FAS (Pharmingen, San Diego, CA, USA), mouse anti-Bcl-2 (Santa
Cruz, Santa Cruz, CA, USA), or rabbit anti-poly(ADP-ribose)
polymerase (PARP) antibody (Athens Biotech, Athens, GA, USA).
After washing three times in TBST for 10min each, the blots were
incubated with anti-mouse or anti-goat IgG horseradish per-
oxidase conjugate (1:10000 dilution, Sigma, St Louis, MO, USA)
for 1h at room temperature. Antigen was detected using standard
chemical luminescence methodology (ECL; Amersham Pharmacia
Biotech, Piscataway, NJ, USA).
Cell viability assay
Cell viability was determined using a modified MTT assay
(Griscelli et al, 2000). Briefly, 1000–5000cellswell
 1 were plated
in 24-well plates and incubated overnight. Cells were then treated
with 0.5–10mgml
 1 cerulenin for 24–144h. At the end of the
follow-up period, MTT in PBS was added and the cultures were
incubated for 4h at 371C. The dark crystals formed were dissolved
by adding to the wells an equal volume of SDS/dimethylformamide
(DMF) extraction buffer (20% SDS and 50% N, N-DMF (pH 4.7), in
PBS). Subsequently, plates were incubated overnight at 371C. A
100ml aliquot of the soluble fraction was transferred into 96-well
microplates, and the absorbance at 570nm was measured using an
ELISA plate reader.
Clonogenic survival assay
Clonogenic survival assays were performed as described previously
(Vartak et al, 1998). Two hundred and fifty to 2000 cells were
plated in 60mm dishes and incubated overnight. Cells were then
treated with 0–10mgml
 1 cerulenin and cultured until colonies
had formed (10–14 days). Cells were then fixed for 10min in a
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ssolution containing 10% acetate and 10% methanol. The cells were
then stained with 0.4% crystal violet for another 10min. The
crystal violet was removed and cells were washed with tap water
until clear. Colonies containing X50 cells were counted. For each
experiment, four culture dishes were performed and experiments
were carried out in triplicate. Surviving fraction was calculated
from the number of colonies formed in the cerulenin-treated
dishes compared with the number formed in the untreated control,
where plating efficiency is defined as the percentage of cells plated
that form colonies, and surviving fraction¼number of colonies
formed/(number of cells plated plating efficiency).
Irradiation
Cells were irradiated with a range of single doses of 0–8Gy of g rays
using a
137Cs self-shielded irradiator at a dose rate of 4.0Gymin
 1.
All irradiations were performed at room temperature; control cells
received sham irradiation. After irradiation, the culture plates were
returned to the incubator and maintained at 371C for 96h. Cell
viability was assessed using the MTT assay described above.
Flow cytometric analysis of cell cycle status
Flow cytometric evaluation of the cell cycle was performed using a
modified protocol (Amant et al, 2003). Briefly, 5 10
5 cells were
plated on 100mm dishes in medium complemented with 10% FBS
overnight. The culture medium was then replaced using serum-free
medium for 24h and the cells treated with 0–10mgml
 1 cerulenin
for 24h. Cells were then trypsinised and collected into ice-cold
PBS, and fixed with ice-cold 70% ethanol in PBS for at least 24h at
41C. Cells were then stained using 1ml propidium iodide (PI)
solution (20mgl
 1 PI and 20mgl
 1 RNase in PBS) for 3h and read
on a flow cytometer (Beckman-Coulter, Fullerton, CA, USA).
Fatty acid synthase shRNA constructs
The nucleotide targets of the FAS coding sequence were selected
based on previously published experiments (De Schrijver et al,
2003) and computer-based target analysis using siRNA Target
Finder (Ambion Inc., Austin, TX, USA). Two 19 base pair siRNA
oligonucleotides were used in our study according to siRNA
selective guidelines (Ambion Inc.). The first oligonucleotide was
AACCCTGAGATCCCAGCGCTG, corresponding to the nucleotides
1212–1231 of human FAS; the second oligonucleotide was
AAGCAGGCACACACGATGGAC, corresponding to the nucleo-
tides 329–348. The two target sequences were aligned to the
human genome in a BLAST search to eliminate those with
significant homology to other genes. A scrambled nucleotide
sequence was designed and used as the negative control. The loop
sequences and overhangs were added to form the short hairpin
constructs. Then, the short hairpin RNA (shRNA) encoding
oligonucleotides were cloned into the BamH1 and HindIII
restriction sites downstream of the H1 promoter in pSilencer
3.0-H1 according to the manufacturers’ instructions (Invitrogen,
Grand Island, NY, USA).
Transient transfection
Transient transfections were performed using Lipofectamine
according to the manufacturer’s instructions (Invitrogen). Briefly,
5 10
6 cells were plated in a 60mm dish supplied with 5ml media
for 24h. Cells were then washed twice with serum- and antibiotic-
free DMEM medium. Four micrograms of FAS RNAi plasmids/
scrambled negative control plasmid and 20ml Lipofectamine were
premixed for 20min and applied to cells in 4ml serum- and
antibiotic-free DMEM medium. After 4h, the serum- and
antibiotic-free DMEM medium was replaced with 5ml of complete
medium.
Stable transfection
U251 cells were grown on 60mm dishes for 24h and were then
transfected with 2mg of the endoplasmic reticulum (ER)-targeted
GFP-Bcl-2 expression vector, wild-type (WT) GFP-Bcl-2 expres-
sion vector, or empty vector (gift of Dr Clark W Distelhorst, Case
Western Reserve University Medical School and University
Hospitals of Cleveland, Cleveland, OH, USA) using Lipofectamine
plus reagent according to manufacturer’s protocol (Life Techno-
logies). The positive transfected cells were selected in the presence
of the neomycin-analogue G418 (800mgml
 1).
Dominant-negative FADD expression
Recombinant doxycycline (Dox)-regulated YFP and dominant-
negative YFP-FADD-DN adenoviruses were made using the
AdenoX Tet-off kit from Clontech (Palo Alto, CA, USA). Viruses
were produced according to the manufacturer’s instructions.
Dominant-negative adenovirus FADD-DN or adenovirus YFP
(empty vector) were co-infected into U251 and SNB-19 glioma
cells with a Tet repressor virus. Once FAD-DN was expressed at
high levels, as demonstrated by robust YFP fluorescence, cells were
treated as required.
Statistical analysis
Statistical analysis was carried out using one-sample Student’s
t-test to compare differences between the treated cells and their
appropriate controls. A P-value of o0.05 was considered
significant.
RESULTS
Fatty acid synthase is overexpressed in human and rat
glioma cell lines as well as in human glioma tissue samples
To determine if there is differential expression in glioma cells
compared with normal brain cells, we measured FAS protein levels
in six human glioma cell lines, U251, U373, U138, U118, U87, and
SNB-19 and in two rat glioma cell lines, C6 and 36B10, as well as in
primary rat astrocytes. Cells were cultured and lysed in 500ml lysis
buffer containing 50mM Tris-HCl (pH 7.4), 150mM NaCl, 1% NP-
40, 0.25% Na-deoxycholate, and 1mM of EDTA, PMSF, Na3VO4
and NaF, and proteinase inhibitors. Fatty acid synthase protein
levels were analysed by Western blotting. As shown in Figure 1A,
a low level of FAS protein was detected in normal primary
astrocytes. In contrast, markedly elevated levels of FAS protein
were observed in the entire human and rat glioma cell lines.
Densitometric analysis revealed 4- to 20-fold increases in FAS
expression in the glioma cell lines in comparison with that seen in
primary rat astrocytes (Figure 1B). Elevated levels of FAS protein,
ranging from 2- to 3.5-fold increases, were also observed in lysates
of human glioma tissue samples compared with those obtained
from normal human brain (Figure 1C and D).
Treating glioma cells with the FAS inhibitor cerulenin
leads to inhibition of fatty acid synthesis
Cerulenin, a potent noncompetitive pharmacological inhibitor of
FAS, binds covalently to the active site of the condensing enzyme
region, inactivating a key enzyme step in fatty acid synthesis. To
confirm the inhibitory effect of cerulenin on FAS in glioma cells,
fatty acid synthesis activity was measured using the
14C-labelled
acetic acid method (Rashid et al, 1997). U251 and SNB-19 human
glioma as well as C6 rat glioma cells were incubated with or
without cerulenin for 2h. After labelling with
14C-actic acid, the
total lipid was extracted and the amount of
14C incorporated in the
extracted total lipids was determined using liquid scintillation
FAS inhibition leads to glioma cell cytotoxicity
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scounting. As shown in Figure 2, endogenous fatty acid synthesis in
cerulenin-treated glioma cells decreased by approximately 50% in
SNB-19, U251, and C6 cells compared with untreated controls.
Fatty acid synthase activity was not detectable in primary rat
astrocytes (data not shown).
Incubating glioma cells with cerulenin leads to selective
time- and dose-dependent decreases in glioma cell viability
and survival; normal astrocytes appear unaffected
To demonstrate whether cerulenin is selectively cytotoxic to
glioma cells, we measured the effects of cerulenin on glioma cells
and primary rat astrocytes using the MTT and/or clonogenic assay.
U251, SNB-19, U87, U118 human, and C6 rat glioma cells were
treated with 0–15mgml
 1 cerulenin for 24 and 96h. We observed
rounded up cells following incubation with higher doses (Figure
3A and B) in 24h and cell death. As shown in Figure 3C, the mean
IC50 values for U251 cells were 4.7 and 2.3mgml
 1 at 24 and 96h,
respectively. SNB-19 glioma cells showed a similar cytotoxic
response to treatment with cerulenin; the mean IC50 values for
SNB-19 cells were 5.3 and 2.6mgml
 1 at 24 and 96h, respectively
(Figure 4A). Moreover, treatment with cerulenin led to a
significant reduction in glioma cell clonogenic survival; incubating
SNB-19 cells with 3mgml
 1 cerulenin reduced clonogenic cell
survival by 97% compared to non-treated controls (Figure 4B). We
also compared the cytoxicity of cerulenin to C6 rat glioma cells and
to normal primary rat astrocytes. After treatment with 10mgml
 1
of cerulenin for 24h, glioma cell viability was reduced to less than
10%; the mean IC50 value was 6.5mgml
 1 (Figure 4C). In contrast,
primary astrocytes appeared resistant to cerulenin treatment.
Incubating astrocytes with 0.5–7.5mgml
 1 cerulenin for 24h failed
to affect cell viability (Figure 4D).
Cerulenin-induced cell death occurs via an apoptotic
mechanism
Poly(ADP-ribose) polymerase, an enzyme catalysing the poly(ADP-
ribosyl)ation of various nuclear proteins with NAD, has been
suggested to contribute to cell death by depleting the cell of NAD
and ATP (Berger et al, 1983). Poly(ADP-ribose) polymerase cleavage
is a well-established marker for apoptosis. To determine whether
apoptosis is involved in cerulenin-induced cell cytotoxicity, we
measured PARP cleavage as well as assessing morphological
changes. As noted above, cell morphology was changed; cells
appeared rounded up after incubation with cerulenin, resulting in
cell death. To determine PARP cleavage, U251 and SNB-19 cells
were treated with 0–10.0mgml
 1 cerulenin for 24h and Western
blot analysis was used to study the alterations in protein level of
PARP in treated and non-treated glioma cells. Treatment with
cerulenin led to a dose-dependent increase in cleaved PARP protein
in both glioma cell lines (Figure 5).
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Figure 1 Fatty acid synthase is overexpressed in human and rat glioma cell lines and in human glioma tissue compared with primary rat astrocytes and
normal human brain tissue, respectively. U138, U251, U373, SNB-19 human, and C6 rat glioma cells, as well as primary rat astrocytes were grown on
100mm dishes until 90% confluent. The protein level of FAS was analysed by Western immunoblotting using a monoclonal mouse anti-FAS antibody; b-actin
protein level was used as a loading control. (A) A representative Western Blot indicating the differential expression of FAS in rat and human glioma cell lies
as well as primary rat astrocytes. (C) The mean densitometric values obtained from two independent experiments. (B) A Western blot of lysates obtained
from normal human brain as well as several human glioma tissue samples. (D) The densitometric analysis of these blots.
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Figure 2 Treating glioma cells with the FAS inhibitor cerulenin leads to
inhibition of fatty acid synthesis. U251 and SNB-19 human and C6 rat
glioma cells were treated with 5mgml
 1 cerulenin for 2h. Fatty acid
synthesis activity was then measured using the
14C-labelled acetate assay.
Lipids were extracted and cerulenin-induced inhibition of labelled acetate
incorporation into lipid was measured using liquid scintillation counting.
Mean7s.e.; n¼3; *Po0.05.
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sOverexpressing Bcl-2 leads to inhibition of cerulenin-
mediated cytotoxicity
Overexpression of the antiapoptotic protein Bcl-2 has been shown
to inhibit cell death induced by several apoptotic signals and/or
mediators (Wang et al, 2001a). To determine if overexpressing
Bcl-2 would result in a similar inhibition of cerulenin-mediated
apoptosis, U251 cells were stably transfected with either WT Bcl-2,
ER-targeted Bcl-2, or empty vector. As shown in Figure 6A,
transducing cells with Bcl-2 led to a marked increase in protein
levels compared with the vector-transduced cells. U251 cells were
then treated with 5mgml
 1 of cerulenin for 24h, and cell viability
assessed using the MTT assay. As noted previously, incubating
U251 cells stably transfected with vector control alone with
5mgml
 1 cerulenin was associated with a reduction in cell viability
to 55.5þ3.4% of controls. Overexpressing ER/Bcl-2 and WT/Bcl-2
increased cell viability to 71.0þ3.2 and 85.972.8%, respectively
(Po0.05; Figure 6).
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Figure 3 Cerulenin reduces U251 cell viability in a time- and dose-
dependent manner. 5 10
4 or 5000 U251 human glioma cells were
seeded into 24-well plates and treated with 0–10mgml
 1 cerulenin for 24
and 96h, respectively. Cell viability was assessed using the MTT assy. (A)
The morphological appearance of DMSO-treated control cells observed
24h after treatment. (B) Incubating U251 glioma cells with cerulenin for
24h resulted in the cells adopting a rounded up appearance. (C) Incubating
U251 glioma cells with cerulenin cells led to a time- and dose-dependent
reduction in cell viability. Mean7s.e.; n¼3.
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Figure 4 Cerulenin selectively reduces glioma cell viability and clonogenic survival; astrocytes are unaffected. 5 10
4 and 5000 SNB-19 human glioma
cells were seeded into 24-well plates and treated with 0–10mgml
 1 cerulenin for 24 and 96h, respectively. Cell viability was assessed using the MTT assay.
To determine clonogenic survival, 500–2000 cells were seeded into 60mm dishes and treated with 0–10mgml
 1 cerulenin for 10–15 days. Cells were
fixed and stained with violet blue and colonies were counted using a colony counter. (A) Incubating SNB-19 cells with cerulenin led to a time- and dose-
dependent reduction in cell viability. (B) A dose-dependent cerulenin-mediated reduction in clonogenic survival. (C) Incubating C6 rat glioma cells with
cerulenin led to a time- and dose-dependent reduction in cell viability. In contrast, (D) shows that incubating primary rat astrocytes with 0.5–7.5mgml
 1
cerulenin for 24h did not affect cell viability.
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Figure 5 Cerulenin induces PARP cleavage in human glioma cells. U251
and SNB-19 cells were treated with 0–10mgml
 1 cerulenin for 24h and
then collected and lysed using lysis buffer. Poly(ADP-ribose) polymerase,
cleaved PARP, and b-actin protein levels were analysed using Western blot.
Representative Western blots show that cerulenin treatment was
associated with dose-dependent increases in cleavage of PARP in both
U251 (A) and SNB-19 (B) glioma cells. Data represent results of two
independent experiments.
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cerulenin-induced apoptosis
FADD-DN is a dominant-negative form of the FADD protein that
blocks all known death receptor-induced apoptotic pathways.
Activation of the death receptor pathway has been implicated in
the mechanism of various chemotherapeutic agents that can work
by upregulating death receptor levels or by raising autocrine
production of death ligand. To test if such pathways contribute to
cerulenin-induced apoptosis, U251 and SNB-19 cells were co-
infected with adenoviruses expressing YFP or YFP-tagged FADD-DN.
Fluorescence could be observed in infected cells (Figure 7B). After
co-infection for 48h, uninfected control cells, YFP-expressing cells,
and YFP-FADD-DN-expressing cells were treated with 0–
10mgml
 1 cerulenin for 24h and the MTT assay was performed
to measure cell viability. As shown in Figure 7C and D, no
significant differences in cell viability were found in the various
groups, indicating that the death receptor pathway is not
associated with FAS inhibition-induced cell apoptosis.
Treating human glioma cells with cerulenin leads to an
S-phase cell cycle block
We hypothesised that the cerulenin-induced cell growth inhibition
and death might involve cell cycle arrest. To test our hypothesis,
we performed flow cytometry analysis. U251 and SNB-19 human
glioma cells were treated with DMSO, 1 or 3mgml
 1 cerulenin for
24h. The cells were then collected and stained with PI for flow
cytometry analysis. Representative cell cycle profiles are shown in
Figure 8. After treatment with cerulenin for 24h, the number of
U251 cells in S phase increased markedly to 58% of the total cell
population compared with controls (23%). A similar increase in
the % of cells in S phase was seen 24h after treatment of SNB-19
cells with cerulenin (Figure 8). These results suggest that
cerulenin-mediated FAS inhibition induced an S-phase block in
glioma cells.
Pretreating glioma cells with cerulenin does not alter
radiosensitivity
Cell radiosensitivity is cell cycle dependent; cells present in the S
phase are relatively radioresistant as compared with cells in other
phases of the cell cycle (Pawlik and Keyomarsi, 2004). As treating
glioma cells with cerulenin induced an S-phase block, we
hypothesised that irradiating glioma cells in the presence of
cerulenin would lead to either no effect or increased radio-
resistance. As shown in Figure 9A, there was no difference in
viability between glioma cells treated with 0.5–4.0 mgml
 1 of
cerulenin 2h before irradiation with a single dose of 5Gy of
137Cs g
rays when compared with glioma cells treated with radiation alone.
Increasing the time the cells were treated with cerulenin to 8h
before irradiation similarly failed to alter glioma cell radio-
sensitivity. Irradiating cerulenin-treated cells with single doses of
40
50
60
70
80
90
100
C
e
l
l
 
v
i
a
b
i
l
i
t
y
 
(
%
 
o
f
 
u
n
t
r
e
a
t
e
d
 
g
r
o
u
p
)
*
*
U251
Bcl-2-ER
Bcl-2-WT
Vector ER/Bcl-2 WT/Bcl-2
Bcl-2
 -Actin
Figure 6 Bcl-2 overexpression protects U251 cells from cerulenin-
induced cytotoxicity. U251 cells stably transfected with empty vector, ER-
targeted vector, or WT Bcl-2 vector showed a marked increase in levels of
Bcl-2 immunoreactive protein (A). Cells were treated with 5mgml
 1
cerulenin for 24h. Cell viability was then assessed using the MTT assay (B).
Mean7s.e.; n¼4, Po0.05.
U251
0
01 351 0
0.2
0.4
0.6
0.8
1
1.2
C
e
l
l
 
v
i
a
b
i
l
i
t
y
0
0.2
0.4
0.6
0.8
1
1.2
C
e
l
l
 
v
i
a
b
i
l
i
t
y
DMSO
YFP
FADD-DN
Control
YFP
FADD-DN
SNB-19
Cerulenin (   g ml−1)
0135 1 0
Cerulenin (   g ml−1)
AB
C D
Figure 7 The death receptor FADD pathway is not involved in cerulenin-induced apoptosis. U251 and SNB-19 human glioma cells were co-infected with
adenoviruses expressing YFP or TFP-tagged FADD-DN. (A) U251 cells treated with DMSO, (B) U251 cells co-infected with YFP-FADD-DN. Cells were
then treated with 0–10mgml
 1 cerulenin for 24h and cell viability was then assessed using the MTT assay. Co-infection with YFP or YFP-FADD-DN failed
to inhibit the cerulenin-mediated glioma cell cytotoxicity.
FAS inhibition leads to glioma cell cytotoxicity
W Zhao et al
874
British Journal of Cancer (2006) 95(7), 869–878 & 2006 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s2, 4, or 8Gy had no affect on glioma cell radiosensitivity. Figure 9B
shows data for glioma cells treated with cerulenin 8h before a
single dose of 4Gy; a similar response was seen after doses of 2 and
8Gy (data not shown).
Fatty acid synthase shRNA transfection leads to
downregulation of FAS expression and enzymatic activity
that is associated with decreased glioma cell viability
To confirm that the effects of cerulenin were due to inhibition of
FAS, we used RNAi to knock down FAS protein levels. To identify
effective RNAi against FAS expression, we tested two different
plasmid-based hairpin constructs of FAS RNAi; a scrambled
sequence was used as the negative control. The shRNAs encoding
oligonucleotides are shown in Figure 10B. They were cloned into
the BamH1 and HindIII restriction sites downstream of the H1
promoter in pSilencer 3.0-H1 (Figure 10A). U251 and SNB-19 cells
were seeded into 60mm dishes for 24h and transfected with 2 and
4mg FAS shRNA DNA for a further 72h. Cells were then lysed and
FAS protein expression analysed using Western blot analysis. As
shown in Figure 10C, scrambled shRNA (control) had no effect on
FAS expression. In contrast, FAS shRNA1 and FAS shRNA2
reduced significantly FAS protein levels. Moreover, this reduction
in FAS protein was associated with a significant (Po0.05)
reduction in FAS enzymatic activity (Figure 10D). To test the
effects of RNAi-mediated FAS silencing on glioma cell growth,
SNB-19 cells were transiently transfected with a range of
concentrations of plasmid DNA of scrambled shRNA and FAS
shRNA for 72h. Cytotoxicity was determined using the MTT assay.
As shown in Figure 10E, cell viability was dose-dependently
reduced in glioma cells transfected with FAS RNAi. These data
confirm the effect of cerulenin as being FAS-specific.
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sDISCUSSION
Our data reveal, for the first time, that the levels of FAS expression
observed in a variety of rat and human glioma cell lines and several
human glioma tissue samples are higher compared to their normal
cell counterpart, the astrocyte, as well as normal human brain
tissue, respectively. Mammalian FAS is a multifunctional enzyme
complex that catalyses the synthesis of palmitate from acetyl-CoA
and malonyl-CoA with NADPH as a provider of reducing
equivalents (Kuhajda, 2006). Humans take up large amount of
proteins and lipids through their daily diet. Therefore, the levels of
FAS in most tissues are low. In human tissue, FAS is distributed in
cells involved in lipid metabolism and in hormone-sensitive cells,
such as adipocytes, hepatocytes, sebaceous glands, and type II
alveolar cells (Weiss et al, 1986). High FAS activity was observed in
foetal brain tissue and gradually declined following aging (Salles
et al, 2002). FAS mRNA level in 20-day-old rat brain was about
20% compared with that measured in 5-day-old brain (Garbay
et al, 1997; Muse et al, 2001). In the adult rat brain,
immunohistochemistical analysis for FAS revealed positive stain-
ing cells in cortical neurons of the frontooccipital lobes; only weak
staining was observed in astrocytes (Kusakabe et al, 2000).
Glioma cell FAS expression has not been reported previously.
We found a marked differential expression of FAS in glioma and
normal astrocytes. A similar upregulation of FAS expression was
noted in lysates of human glioma samples compared with lysates of
FAS siRNA
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Figure 10 Fatty acid synthase shRNA transfection downregulates FAS expression and inhibits glioma cell growth. Sense and antisense oligonucleotides
encoding the shRNAs (B) were cloned into the BamH1 and HindIII restriction sites downstream of the H1 promoter in pSilencer 3.0H-1 (A). U251 and
SNB-19 cells were seeded into 60mm dishes for 24h and transfected with 2 and 4mg FAS shRNA DNA for a further 72h. Cells were then lysed and FAS
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snormal human brain tissue. Administration of the FAS inhibitor
cerulenin led to significant time- and dose-dependent decreases in
glioma cell viability and survival. Low doses of cerulenin caused
cell cycle arrest, whereas higher doses led to cytotoxicity. In
contrast, normal astrocytes were unaffected. These findings
suggest that FAS might be a novel target for antiglioma therapy.
The mechanism(s) underlying malignant cell cytotoxicity
following FAS inhibition has been studied in several cancer cell
lines. FAS inhibition can cause accumulation of malonyl-CoA,
which leads to inhibition of carnitine palmitoyltransferase-1 and,
indirectly, the fatty acid oxidation pathway (Thupari et al, 2001).
Rapid accumulation of malonyl-CoA was observed after FAS
inhibition (Kuhajda et al, 2000). Blocking the accumulation of
malonyl-CoA using 5-(tetradecyloxy)-2-furoic acid, an inhibitor of
acetyl-CoA carboxylase, reduced significantly cerulenin- and C75-
induced cytotoxicity and inhibition of breast tumour growth.
Apoptosis appeared to play a major role in this cell death. In our
experiments, we demonstrated clearly that PARP cleavage, an
apoptotic marker, was induced in cerulenin-treated U251 and
SNB-19 cells; this was associated with significant cytotoxicity.
Heiligtag et al (2002) reported that cerulenin is an effective inducer
of apoptosis in WT or mutant p53 neuroblastoma, melanoma, and
colon carcinoma cell lines; normal human cells were resistant to
cerulenin-induced apoptosis. Further, apoptosis was mediated
both by overexpression of proapoptotic Bax, in a p53-independent
manner, and by a rapid release of mitochondrial cytochrome c,
leading to activation of caspase 3 and 9. Data presented in the
current studies confirm a P53-independent apoptotic response in
glioma cells following FAS inhibition; similar glioma cell
cytotoxicity was observed in either P53 WT (U87 and U118) or
in P53 mutant glioma cell lines (U251, SNB-19, U138, and C6).
Bcl-2, a protooncogene that enhances cell survival by inhibiting
apoptosis (Vaux et al, 1988), is localised in the ER, the outer
mitochondrial membrane, and the nuclear envelope (Akao et al,
1994). Stable expression of Bcl-2 or Bcl-2 targeted to the ER has
been shown to inhibit apoptosis (Wang et al, 2001a). Similarly, we
observed that stable expression of Bcl-2-targeted to the ER or WT
Bcl-2 expressed not only in the ER but also in the mitochondria
and nuclei, reduced cerulenin-mediated glioma cell death. These
data provide additional support for the hypothesis that cerulenin-
mediated toxicity is due, in part, to an increase in apoptotic cell
death. To investigate further the apoptotic response, the role of the
death receptor pathway in cerulenin-mediated apoptosis was
evaluated by infecting glioma cells with a FADD-DN adenovirus.
In agreement with the previously suggested mechanism involving
cytochrome c release (Heiligtag et al, 2002) FADD-DN, which
inhibits all the known death receptor pathways, had no effect on
cerulenin-induced glioma cell death.
Cerulenin- and C75-mediated alterations in cell cycle progres-
sion have been observed in a variety of cancer cell lines. Although
FAS inhibition can lead to a block in the cell cycle before G1
(Kuhajda et al, 2000), there are data that support an S-phase arrest
in breast cancer cells (Zhou et al, 2003) and in colon carcinoma
cells (Pizer et al, 2001). In the current study, we demonstrated a
marked, dose-dependent S-phase block at 24h after treatment. The
mechanism(s) of FAS inhibition-induced cell cycle arrest is still
not clear. De novo fatty acid synthesis by tumour cells accounted
for more than 93% of total lipid fatty acids in an experimental
tumour model, indicating that endogenous fatty acid synthesis
could be a significant source of fatty acids for tumour cell growth
and survival (Ookhtens et al, 1984). Most of the fatty acids
produced by tumour cells are incorporated into membrane
phospholipids, and phospholipid synthesis is inhibited when fatty
acid synthesis is inhibited (Pizer et al, 1996; Jackowski et al, 2000).
Phospholipid biosynthesis is greatest during the G1 and S phases,
with doubling of the membrane mass occurring during S phase in
preparation for cell division (Jackowski, 1994). Thus, cells in S
phase should be most sensitive to changes in phospholipid
metabolism. In contrast, cells in S phase are relatively radio-
resistant; the expected outcome would be either no effect or
increased radioresistance. Indeed, as predicted, combining cer-
ulenin treatment with ionising radiation did not alter glioma cell
radioresistance.
We used selective gene silencing by siRNA (Zamore et al, 2000)
to confirm the role of FAS inhibition in glioma cell cytotoxicity.
RNAi-induced knockdown of FAS that led to a significant
reduction in FAS enzymatic activity resulted in a dose-dependent
reduction in glioma cell viability, confirming similar gene silencing
approaches with RNAi described in human LNCaP prostate cancer
cells (De Schrijver et al, 2003).
In conclusion, our studies demonstrate that (1) human and rat
glioma cell lines express high levels of FAS compared with normal
brain astrocytes; high levels of FAS were also seen in human
glioma tissue compared with normal human brain, (2) FAS
inhibition is selectively cytotoxic to glioma cells; normal astrocytes
are unaffected; and (3) both cytotoxic and cytostatic effects
contribute to the cerulenin-mediated effects in glioma cells. These
findings support the hypothesis that FAS might be a novel target
for antiglioma therapy.
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